Publicacions en què col·labora amb Leire Garate Iturriagagoitia (19)

2022

  1. Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts

    American Journal of Hematology

2021

  1. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

2013

  1. Erratum: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia (Oncogene (2013) 32 (803) DOI: 10.1038/onc.2012.593)

    Oncogene

2012

  1. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia (Blood (2007) 109, 8 (3462-3469))

    Blood

  2. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

  3. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia

    PLoS ONE, Vol. 7, Núm. 2

2011

  1. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2

2009

  1. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 27, Núm. 8, pp. 1316-1322

  2. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  3. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

    Molecular Cancer, Vol. 8, pp. 69

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

  3. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation

    Leukemia Research, Vol. 32, Núm. 5, pp. 709-716

2007

  1. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia

    Blood, Vol. 109, Núm. 8, pp. 3462-3469

2006

  1. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

    Oncogene, Vol. 25, Núm. 13, pp. 1862-1870

  2. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia

    International Journal of Cancer, Vol. 118, Núm. 8, pp. 1945-1953

  3. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia

    Clinical Cancer Research, Vol. 12, Núm. 16, pp. 4845-4850

  4. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

    British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144